- Home
- FPF vs KURA Comparison
FPF vs KURA Comparison
Compare FPF & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FPF | KURA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FPF | KURA |
|---|---|---|
| Price | $15.71 | $10.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 202.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $43.11 |
| Revenue Next Year | N/A | $119.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $15.86 | $7.36 |
| 52 Week High | $19.36 | $13.90 |
Technical Indicators
Market Signals| Indicator | FPF | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 19.54 | 44.32 |
| Support Level | N/A | $8.45 |
| Resistance Level | $18.18 | $11.40 |
| Average True Range (ATR) | 0.27 | 0.45 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 2.36 | 34.24 |
Price Performance
Historical ComparisonAbout FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.